Ultragenyx to Participate at Bank of America’s 2025 Healthcare Conference
Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in novel therapies for rare and ultra-rare genetic diseases, announced that CFO and Executive VP Howard Horn will participate in a fireside chat at Bank of America's 2025 Healthcare Conference. The event is scheduled for Tuesday, May 13, 2025, at 8:00 a.m. PT. Investors and interested parties can access both the live and archived webcast of the panel through Ultragenyx's investor relations website.
Ultragenyx Pharmaceutical (NASDAQ: RARE), un'azienda biofarmaceutica specializzata in terapie innovative per malattie genetiche rare e ultra-rare, ha annunciato che il CFO e Vice Presidente Esecutivo Howard Horn parteciperà a una conversazione informale durante la Bank of America's 2025 Healthcare Conference. L'evento è previsto per martedì 13 maggio 2025 alle 8:00 PT. Investitori e interessati potranno seguire la diretta e rivedere la registrazione del webcast sul sito web delle relazioni con gli investitori di Ultragenyx.
Ultragenyx Pharmaceutical (NASDAQ: RARE), una compañía biofarmacéutica especializada en terapias novedosas para enfermedades genéticas raras y ultra-raras, anunció que el CFO y Vicepresidente Ejecutivo Howard Horn participará en una charla informal en la Bank of America's 2025 Healthcare Conference. El evento está programado para el martes 13 de mayo de 2025 a las 8:00 a.m. PT. Los inversores y personas interesadas pueden acceder tanto a la transmisión en vivo como a la grabación del panel a través del sitio web de relaciones con inversores de Ultragenyx.
Ultragenyx Pharmaceutical (NASDAQ: RARE)는 희귀 및 초희귀 유전 질환을 위한 혁신적인 치료법을 전문으로 하는 생명공학 회사로, CFO 겸 부사장 Howard Horn이 Bank of America's 2025 Healthcare Conference에서 대담에 참여할 예정이라고 발표했습니다. 행사는 2025년 5월 13일 화요일 오전 8시(태평양 시간)에 열립니다. 투자자 및 관심 있는 분들은 Ultragenyx 투자자 관계 웹사이트를 통해 생중계와 녹화된 웹캐스트를 모두 시청할 수 있습니다.
Ultragenyx Pharmaceutical (NASDAQ : RARE), une société biopharmaceutique spécialisée dans les thérapies innovantes pour les maladies génétiques rares et ultra-rares, a annoncé que le directeur financier et vice-président exécutif Howard Horn participera à une discussion informelle lors de la Bank of America's 2025 Healthcare Conference. L'événement est prévu pour le mardi 13 mai 2025 à 8h00 heure du Pacifique. Les investisseurs et les parties intéressées pourront accéder à la fois au webcast en direct et à l'archive du panel via le site web des relations investisseurs d'Ultragenyx.
Ultragenyx Pharmaceutical (NASDAQ: RARE), ein biopharmazeutisches Unternehmen, das sich auf neuartige Therapien für seltene und ultra-seltene genetische Erkrankungen spezialisiert hat, gab bekannt, dass CFO und Executive VP Howard Horn an einem Gespräch bei der Bank of America's 2025 Healthcare Conference teilnehmen wird. Die Veranstaltung ist für Dienstag, den 13. Mai 2025, um 8:00 Uhr PT geplant. Investoren und Interessierte können sowohl den Live-Stream als auch die Aufzeichnung des Panels über die Investor-Relations-Website von Ultragenyx abrufen.
- None.
- None.
NOVATO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Howard Horn, the company's chief financial officer and executive vice president, will participate in a fireside at Bank of America’s 2025 Healthcare Conference on Tuesday, May 13, 2025, at 8:00 a.m. PT.
The live and archived webcast of the panel will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contacts – Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
ir@ultragenyx.com
FAQ
When is Ultragenyx (RARE) presenting at Bank of America's 2025 Healthcare Conference?
Who will represent Ultragenyx (RARE) at the Bank of America Healthcare Conference 2025?
How can investors access Ultragenyx's (RARE) presentation at the Bank of America Healthcare Conference?
What type of company is Ultragenyx Pharmaceutical (RARE)?
